DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
98	好酸球性消化管疾患	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03656380 (ClinicalTrials.gov)	March 20, 2019	30/8/2018	Mepo for EoE Study	A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant Symptoms	EoE;Eosinophilic Esophagitis	Drug: Mepolizumab 300 mg;Drug: Mepolizumab 100 mg;Other: Placebo	University of North Carolina, Chapel Hill	GlaxoSmithKline;University of Utah;Northwestern University;MNGI Digestive Health, P.A.	Recruiting	16 Years	75 Years	All	72	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03656380
(ClinicalTrials.gov)

March 20, 2019

30/8/2018

Mepo for EoE Study

A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant Symptoms

EoE;Eosinophilic Esophagitis

Drug: Mepolizumab 300 mg;Drug: Mepolizumab 100 mg;Other: Placebo

University of North Carolina, Chapel Hill

GlaxoSmithKline;University of Utah;Northwestern University;MNGI Digestive Health, P.A.

Recruiting

16 Years

75 Years

All

Phase 2

United States